Alterity Therapeutics is aiming to shift the narrative for patients with Multiple System Atrophy with its lead drug ATH434. .

Nonmodifiable risk factors for DLB include age and family history. Risk increases substantially in individuals with a ...

Researchers have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson's disease.

Multiple-system atrophy is an adult-onset, fatal neurodegenerative disease characterized by progressive autonomic failure, parkinsonian features, and cerebellar and pyramidal features in various ...

Using a portable device developed at Drexel University, researchers at Albert Einstein College of Medicine have identified differences in brain activation patterns associated with postural stability ...

Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia Juan L Molina, María Calvó, Eduardo Padilla, Mara Balda, ...

Neurology > Parkinson's Disease Blood, CSF Marker Detects Parkinsonian Disorders — Enzyme also identified preclinical Lewy body disease by Judy George, Deputy Managing Editor, MedPage Today ...

The data to be presented further strengthens the evidence that ATH434 is neuroprotective in brain regions implicated in Parkinsonian disorders.

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund ...

Brain imaging technology offers new approach for studying Parkinsonian syndromes Date: December 18, 2015 Source: Drexel University Summary: Using a portable device, researchers have identified ...